Dive Brief:
- Catalent licensed the anti-body drug conjugate (ADC) known as CD22-4AP to Triphase Accelerator sot that it can expand its footprint in oncology development.
- NJ-based Catalent will receive an undisclosed upfront payment and milestone payments related to development and commercialization. It also has the potential to receive royalties on product sales.
- Triphase will contract out the development, manufacturing and analytical services to Catalent in an effort to speed up the time through the clinic.
Dive Insight:
Triphase, which specializes in advancing compounds from preclinical to proof-of concept, seeks to expand its clinical development related to oncology and blood cancers through its deal with Catalent.
Its partnership with Catalent "is a logical progression for us to explore other approaches for other hematologic tumors," said Mohit Trikha, chief science officer at Triphase in a statement.
Catalent said it seeks to expand its development of CD22-4AP, a site specific ADC that targets CD22, expressed in 90% of B-cell malignancies. CD22 is a target with potential in the treatment of non-Hodgkin’s lymphoma and acute lymphoid leukemia. The SMARTag technology program was developed by Catalent’s wholly owned subsidiary, Redwood Biosciences.
"Triphase has demonstrated expertise and a track record in advancing pre-clinical oncology candidates to clinical proof of concept," said Mike Riley, Catalent Biologics’ vice president and general manager. "We look forward to leveraging Triphase’s expertise in combination with our proprietary SMARTag technology and supporting infrastructure to bring this potential transformational treatment to patients."
